Suppr超能文献

磁共振成像引导下大分割消融放疗治疗肿瘤血栓延伸至右心房的肝细胞癌

Magnetic Resonance Image-Guided Hypofractionated Ablative Radiation Therapy for Hepatocellular Carcinoma With Tumor Thrombus Extending to the Right Atrium.

作者信息

Dincer Neris, Ugurluer Gamze, Zoto Mustafayev Teuta, Gungor Gorkem, Atalar Banu, Guven Koray, Ozyar Enis

机构信息

Radiation Oncology, Acibadem University, Istanbul, TUR.

Radiation Oncology, Acibadem Maslak Hospital, Istanbul, TUR.

出版信息

Cureus. 2022 Apr 9;14(4):e23981. doi: 10.7759/cureus.23981. eCollection 2022 Apr.

Abstract

Hepatocellular carcinoma (HCC) presenting with tumor thrombus (TT) and inferior vena cava (IVC)/right atrium (RA) infringement point to an advanced-stage disease that is deemed inoperable. Stereotactic body radiotherapy is an emerging treatment option for this group of patients with promising outcomes in recent studies that are comparable to conventional treatment methods, namely, transarterial chemoembolization and transarterial radioembolization. Here, we report a case of HCC with RA extension through the IVC. The patient was referred to our clinic for treatment options, and he was found suitable for magnetic resonance imaging-guided radiotherapy (MRgRT). We treated the patient with MRgRT in five fractions to a total dose of 40 Gray. The tumor was tracked during the treatment sessions, and adaptive treatment planning was performed before each fraction. The patient tolerated the treatment well with no acute grade 3-4 toxicities. The last follow-up showed that the patient had a complete biochemical response and is now a candidate for an orthotopic liver transplant. To our knowledge, this report is the first to document the MRgRT treatment of an HCC with TT and RA extension. MRgRT is safe and feasible for this patient group and can be an effective bridging therapy for liver transplants.

摘要

肝细胞癌(HCC)合并肿瘤血栓(TT)及侵犯下腔静脉(IVC)/右心房(RA)提示疾病已处于晚期,被认为无法手术切除。立体定向体部放疗是针对这类患者的一种新兴治疗选择,近期研究显示其疗效良好,可与传统治疗方法(即经动脉化疗栓塞和经动脉放射性栓塞)相媲美。在此,我们报告一例HCC侵犯范围延伸至右心房且经下腔静脉蔓延的病例。该患者因寻求治疗方案前来我院就诊,经检查发现其适合接受磁共振成像引导下放疗(MRgRT)。我们采用MRgRT对该患者进行治疗,分5次照射,总剂量达40格雷。在治疗过程中对肿瘤进行跟踪,并在每次照射前进行适应性治疗计划调整。患者对治疗耐受性良好,未出现3 - 4级急性毒性反应。最后一次随访显示患者出现完全生化缓解,目前是原位肝移植的候选对象。据我们所知,本报告首次记录了采用MRgRT治疗合并TT及RA侵犯的HCC病例。MRgRT对于该类患者安全可行,可作为肝移植的有效桥接治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f227/9084425/31fae49c6c5a/cureus-0014-00000023981-i01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验